Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has...
Vaccine
WORK Medical Technology Group LTD Announces Pricing of Initial Public Offering
Hangzhou, China, Aug. 23, 2024 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (the "Company"), a supplier of medical devices...
Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna’s COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1
CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from...
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following...
Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Aug. 21,...
ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (“ANEW” or the “Company”) (Nasdaq: WENA) announced the signing...
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update
Oslo, August 21, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its...
Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting
REDWOOD CITY, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced...
Infectious Disease Expert Kelly Warfield Named Sabin’s New R&D President
caption: Sabin Vaccine Institute Research & Development President Kelly Warfield WASHINGTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Virologist and vaccine...
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication
CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department More than 27,569 individuals...
Sustainable Agriculture: The Growing Need for Biotech Innovations in the World’s Food Supplies
USA News Group Commentary Issued on behalf of BioVaxys Technology Corp. VANCOUVER, BC, Aug. 19, 2024 /PRNewswire/ -- USA News...
Defence Investigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders
COPENHAGEN, Denmark, August 17, 2024 – Bavarian Nordic A/S (OMX: BAVA) provides an update on plans for securing supply of...
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company...
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's...
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBMPart B expected...
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company...
Chromatography Market size is set to grow by USD 3.99 billion from 2024-2028, Increasing number of conferences and symposiums to boost the market growth, Technavio
NEW YORK, Aug. 14, 2024 /PRNewswire/ -- The global chromatography market size is estimated to grow by USD 3.99 billion...
Veridix AI, part of Emmes Group, Announces New Protocol Digitization Capabilities
Protocol digitization extracts structured data elements from unstructured textAutomates database study builds, reducing build timelines by up to 30%Deployed within...